Back

Sana Biotechnology, Inc.

Data quality: 100%

Oversold

SANA

NASDAQ Healthcare Biotechnology

$2.92

▼ $0.20 (-6.41%)

Mkt Cap: 779.25M

Day Range

$2.86 $3.10

52-Week Range

$1.26 $6.55

Volume

4,522,883

50D / 200D Avg

$4.05 / $3.93

Prev Close

$3.12

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric	Stock	Sector Median
P/E	-3.2	0.4
P/B	4.8	2.9
ROE %	-118.7	3.7
Net Margin %	—	3.9
Rev Growth 5Y %	—	10.0
D/E	0.5	0.2

Analyst Price Target

Hold

$9.00 +208.2%

Low: $7.00 High: $12.00

Forward EPS

-$0.63

Est. Revenue

Earnings Estimates

Period	EPS Est.	Revenue Est.	Analysts
FY2030	-$0.73 -$0.73 – -$0.73	26 M	2
FY2029	-$0.83 -$0.83 – -$0.83	5 M	4
FY2028	-$0.69 -$1.14 – -$0.51	20 M	6

Insider Trading Activity

20 transactions

Date	Insider	Type	Shares	Price	Value
Mar 9, 2026	Wyrick Susan D. See Remarks	other	4,387	$3.13	$13,700
Mar 9, 2026	Harr Steve President & CEO	other	24,345	$3.13	$75,815
Mar 7, 2026	Wyrick Susan D. See Remarks	other	6,500	—	—
Mar 7, 2026	Harr Steve President & CEO	other	100,000	—	—
Mar 6, 2026	Wyrick Susan D. See Remarks	other	20,832	—	—
Mar 6, 2026	Harr Steve President & CEO	other	83,332	—	—
Mar 5, 2026	Harr Steve President & CEO	grant	1,100,000	—	—
Mar 5, 2026	Wyrick Susan D. See Remarks	grant	252,083	—	—
Mar 3, 2026	Wyrick Susan D. See Remarks	other	491	$3.91	$1,920
Mar 2, 2026	Wyrick Susan D. See Remarks	other	3,050	—	—
Feb 17, 2026	Piper Brian EVP, Chief Financial Officer	grant	1,100,000	—	—
Dec 15, 2025	Wyrick Susan D. See Remarks	other	873	$5.22	$4,557
Dec 13, 2025	Wyrick Susan D. See Remarks	other	6,800	—	—
Dec 4, 2025	Wyrick Susan D. See Remarks	other	2,565	$4.44	$11,389
Dec 3, 2025	Wyrick Susan D. See Remarks	other	20,000	—	—
Jun 5, 2025	Rosiello Robert L.	grant	115,000	—	—
Jun 5, 2025	Wilderotter Mary Agnes	grant	80,000	—	—
Jun 5, 2025	NELSEN ROBERT	grant	80,000	—	—
Jun 5, 2025	Bilenker Joshua H.	grant	80,000	—	—
Jun 5, 2025	Yang Patrick Y	grant	80,000	—	—

Key Takeaways

Debt/Equity of 0.49 — conservative balance sheet

Negative free cash flow of -144.77M

PEG of 0.24 suggests growth is underpriced

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-118.70%

ROIC-59.74%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

0.49

Current Ratio1.89

Interest Coverage0.00

Valuation

P/E Ratio

-3.19

P/B Ratio4.84

EV/EBITDAN/A

Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	0.0	Net Income (TTM)	-244.17M
ROE	-118.70%	ROA	-58.57%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-144.77M
ROIC	-59.74%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0.49	Current Ratio	1.89
Interest Coverage	0.00	Dividend Yield	0.00%
Valuation
P/E Ratio	-3.19	P/B Ratio	4.84
P/S Ratio	N/A	PEG Ratio	0.24
EV/EBITDA	N/A	Dividend Yield	0.00%
Market Cap	779.25M	Enterprise Value	786.24M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	0.0	0.0	0.0	0.0	0.0
Net Income	-244.17M	-266.76M	-283.26M	-269.48M	-355.93M
EPS (Diluted)	-0.96	-1.16	-1.46	-1.43	-2.14
Gross Profit	-12.75M	0.0	0.0	0.0	0.0
Operating Income	-190.96M	-272.72M	-293.14M	-272.56M	-356.91M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	416.89M	501.02M	565.30M	822.72M	1.13B
Total Liabilities	256.01M	250.52M	277.79M	323.41M	400.91M
Shareholders' Equity	160.88M	250.50M	287.51M	499.32M	728.50M
Total Debt	78.86M	94.20M	104.10M	108.25M	110.94M
Cash & Equivalents	71.87M	127.57M	133.52M	176.77M	253.03M
Current Assets	148.68M	160.81M	213.52M	444.44M	558.10M
Current Liabilities	78.73M	45.43M	64.49M	111.50M	99.24M